3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Head & Neck
1
Gynecologic
1
Genitourinary
1
Conditions
Warts
2
Melanoma
2
Hyperthermia
2
Uterine Cervical Neoplasms
1
Squamous Cell Carcinoma of Head and Neck
1
Small Cell Lung Carcinoma
1
Sarcoma
1
Prostatic Neoplasms
1
Ovarian Neoplasms
1
Metastatic Castration-resistant Prostate Cancer (mCRPC)
1
Lymphoma, T-Cell
1
Hemorrhage
1
Hematologic Neoplasms
1
Carcinoma, Transitional Cell
1
Carcinoma, Non-Small-Cell Lung
1
Carcinoma
1
Brain Neoplasms
1
Interventions
Etoposide
27
Carboplatin
26
atezolizumab
16
durvalumab
12
Cisplatin
10
Topotecan
9
Drug Therapy
9
PM 01183
7
pembrolizumab
5
Radiotherapy
5
Specimen Handling
4
Paclitaxel
4
Magnetic Resonance Spectroscopy
4
Irinotecan
4
Injections
4
Immunotherapy
4
trilaciclib
3
toripalimab
3
Temozolomide
3
Radiosurgery
3
Bevacizumab
3
AMG 757
3
tislelizumab
2
monalizumab
2
irinotecan sucrosofate
2
enzalutamide
2
apatinib
2
Platinum
2
Nivolumab
2
Itraconazole
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Recruiting
×
Small Cell Lung Carcinoma
×
Solutions
×
Clear all
NCT06022757
2024-02-23
KEYNOTE F19
Evopoint Biosciences Inc.
Phase 1/2
Recruiting
204 enrolled